Pharmaceuticals
Reconcile®
(fluoxetine hydrochloride)
USES
Indicated for the treatment of canine separation anxiety in conjunction with a behavior modification plan.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
See full prescribing information for complete dosing and administration instructions.
| Item # | Product Name | Supplied |
|---|---|---|
| 10034057 | Reconcile® 8 mg Chewable Tablets | 30 ct. bottle |
| 10036844 | Reconcile® 8 mg Chewable Tablets | 90 ct. bottle |
| 10034157 | Reconcile® 16 mg Chewable Tablets | 30 ct. bottle |
| 10036944 | Reconcile® 16 mg Chewable Tablets | 90 ct. bottle |
| 10034257 | Reconcile® 32 mg Chewable Tablets | 30 ct. bottle |
| 10037044 | Reconcile® 32 mg Chewable Tablets | 90 ct. bottle |
| 10034357 | Reconcile® 64 mg Chewable Tablets | 30 ct. bottle |
| 10037144 | Reconcile® 64 mg Chewable Tablets | 90 ct. bottle |
ADDITIONAL RESOURCES
ONLINE RESOURCES
PRODUCT INFORMATION
Active Ingredient(s): fluoxetine hydrochloride
IMPORTANT SAFETY INFORMATION:
The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation. Reconcile chewable tablets are contraindicated for dogs with a history of seizures or when used with MAOIs. For product label, including complete safety information, see package insert.
WARNINGS:
For oral use in dogs only. Not for human use. Keep out of reach of children.
